와이바이오로직스 Stock: price and insider trades · South Korea
3 insiders bought €27k of shares over the last 90 days, the latest by 장명자, filed 15 Oct 2026.
Cluster: 3 buyers in 30 days와이바이오로직스: what insiders have been doing
와이바이오로직스 is a Health Care company. Its directors and officers file their transactions with DART (FSS). In the past year (2 November 2025 to 2 November 2026), 28 filings came from 6 insiders.
Both sides are active: 19 purchases worth €651k and 4 sales worth €412k, from 5 insiders and 2 insiders respectively. The totals do not cover 19 filings with an undisclosed amount. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. One trade stands out by size: a sale of €412k from 박영우, disclosed on 19 March 2026, or 0.47% of market capitalisation. Those buying include 3 chief executives, 2 senior executives and 1 major shareholder.
In all, 1 purchase was made within 30 days of a purchase by another insider of the company. Purchases made close together by different insiders form what is called a cluster. The last insider purchase was made public on 15 October 2026, 26 days ago. Typically, a trade is published a median of 7 days after it takes place. That lag is the time during which only the insider knows about the trade.
Across the 2,655 companies tracked on its exchange, the median is 7 filings; at 28 filings, this issuer sits above that mark. Looking back to 2023, when coverage begins, insiders filed 20 purchases and 8 sales.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and UCB. These figures are compiled from regulatory filings published by DART (FSS). They describe what insiders did and are not a recommendation.
Who traded when
BuySaleSince the insiders bought
- -39.7%Entry ₩14,850 · Close 30 Oct 2026 ₩8,950
- -65.0%Entry ₩25,600 · Close 30 Oct 2026 ₩8,950
- -74.2%Entry ₩34,650 · Close 30 Oct 2026 ₩8,950
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- Other0DART
- 1,040 sharesShareKRXDART:20261015000248Canonical exit: 13 Jan 2027 (T+90)
- 1,000 sharesShareKRXDART:20261015000255Canonical exit: 13 Jan 2027 (T+90)
- 1,425 sharesShareKRXDART:20261014000099Canonical exit: 12 Jan 2027 (T+90)
- 2,500 sharesShareKRXDART:20261014000095Canonical exit: 12 Jan 2027 (T+90)
- Other0DART
- Other0DART
- 3,100 sharesShareKRXDART:20260805000195Canonical exit: 3 Nov 2026 (T+90)
- Other0DART
- 1,800 sharesShareKRXDART:20260803000161Canonical exit: 1 Nov 2026 (T+90)
- Other0DART
- 2,000 sharesShareKRXDART:20260723000101Canonical exit: 21 Oct 2026 (T+90)
- 115,000 sharesKRXDART:20260709000550
- 18,300 sharesKRXDART:20260701000086Canonical exit: 29 Sept 2026 (T+90)
- 12,100 sharesShareKRXDART:20260701000089Canonical exit: 29 Sept 2026 (T+90)
- 1,900 sharesShareKRXDART:20260623000138Canonical exit: 21 Sept 2026 (T+90)
- 1,500 sharesShareKRXDART:20260617000149Canonical exit: 15 Sept 2026 (T+90)
- ●Executives0DART
- 1,500 sharesShareKRXDART:20260610000087Canonical exit: 8 Sept 2026 (T+90)
- 1,300 shares@ ₩15,913.00100.0% of flowShareKRXDART:20260604000173Canonical exit: 2 Sept 2026 (T+90)
- ●Executives0DART
- 60,000 shares@ ₩9,767.000.39% mcap100.0% of flowShareKRXDART:20260416000484Canonical exit: 8 Jul 2026 (T+90)
- 0KRXDART:20260416000451
- 20,000 shares@ ₩25,691.000.34% mcap100.0% of flowShareKRXDART:20260319000817Canonical exit: 15 Jun 2026 (T+90)
- 20,000 shares0.47% mcap100.0% of flowKRXDART:20260319000792
25 of 44 declarations
About 와이바이오로직스
와이바이오로직스 is a company in the healthcare and pharmaceutical sector, listed on the XKRX market. It specializes in the development of biopharmaceutical products.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
